190 related articles for article (PubMed ID: 31574962)
1. Synthesis, Biological Activities and Docking Studies of Novel 4-(Arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors.
Kalinichenko E; Faryna A; Kondrateva V; Vlasova A; Shevchenko V; Melnik A; Avdoshko O; Belko A
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574962
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Asaki T; Sugiyama Y; Hamamoto T; Higashioka M; Umehara M; Naito H; Niwa T
Bioorg Med Chem Lett; 2006 Mar; 16(5):1421-5. PubMed ID: 16332440
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel Bcr-Abl
Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
7. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Li S; Yao Z; Zhao Y; Chen W; Wang H; Kuang X; Zhan W; Yao S; Yu S; Hu W
Bioorg Med Chem Lett; 2012 Aug; 22(16):5279-82. PubMed ID: 22789429
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
[TBL] [Abstract][Full Text] [Related]
10. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Kumar H; Raj U; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
[TBL] [Abstract][Full Text] [Related]
11. Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors.
Xiong H; Cheng J; Zhang J; Zhang Q; Xiao Z; Zhang H; Tang Q; Zheng P
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861448
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Banavath HN; Sharma OP; Kumar MS; Baskaran R
Sci Rep; 2014 Nov; 4():6948. PubMed ID: 25382104
[TBL] [Abstract][Full Text] [Related]
13. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor activities of some new N1-(flavon-6-yl)amidrazone derivatives.
Habashneh AY; El-Abadelah MM; Zihlif MA; Imraish A; Taha MO
Arch Pharm (Weinheim); 2014 Jun; 347(6):415-22. PubMed ID: 24615985
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.
Xie Z; Cheng D; Luo L; Shen G; Pan S; Pan Y; Chen B; Wang X; Liu Z; Zhang Y; Ye F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):905-919. PubMed ID: 29734851
[TBL] [Abstract][Full Text] [Related]
16. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Molecular Docking, Molecular Dynamics Studies, and Biological Evaluation of 4H-Chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylate Derivatives as Potential Antileukemic Agents.
Dolatkhah Z; Javanshir S; Sadr AS; Hosseini J; Sardari S
J Chem Inf Model; 2017 Jun; 57(6):1246-1257. PubMed ID: 28524659
[TBL] [Abstract][Full Text] [Related]
19. Hit discovery of 4-amino-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small library.
Elkamhawy A; Paik S; Hassan AHE; Lee YS; Roh EJ
Bioorg Chem; 2017 Dec; 75():393-405. PubMed ID: 29102722
[TBL] [Abstract][Full Text] [Related]
20. Computational study of molecular electrostatic potential, docking and dynamics simulations of gallic acid derivatives as ABL inhibitors.
Raghi KR; Sherin DR; Saumya MJ; Arun PS; Sobha VN; Manojkumar TK
Comput Biol Chem; 2018 Jun; 74():239-246. PubMed ID: 29660671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
